scholarly journals Curative Effect Analysis of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis with Different Bone Turnover Rates

2018 ◽  
Vol 09 (08) ◽  
pp. 621-628
Author(s):  
Suming Jie ◽  
Jinmei Deng ◽  
Caixia Lin ◽  
Xiuzhen Cai ◽  
Dongmei Cai
Keyword(s):  
Zoledronic Acid ◽  
Bone Turnover ◽  
Postmenopausal Osteoporosis ◽  
Turnover Rates ◽  
Curative Effect ◽  
Effect Analysis

A phase II report of longitudinal bone marker time trends in racially diverse prostate cancer patients receiving zoledronic acid with androgen deprivation

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14568-14568
Author(s):  
V. R. Phooshkooru ◽  
H. J. Spencer ◽  
M. Kohli
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Zoledronic Acid ◽  
Bone Turnover ◽  
Cancer Patients ◽  
Androgen Deprivation ◽  
Control Group ◽  
Turnover Rates ◽  
Mineral Density ◽  
Racially Diverse

14568 Background: Evidence for preventing androgen deprivation (AD) induced osteoporosis with bisphosphonate therapy in prostate cancer patients has emerged largely from trials conducted in caucasian patients. Osteoporosis related skeletal event incidence in African Americans (AA) receiving AD is significantly lower than caucasians and the effect of bisphosphonates therapy uncertain. We conducted a prospective study to evaluate the efficacy of zoledronic acid in preventing osteoporosis in racially diverse population receiving AD. Methods: Asymptomatic, prostate cancer patients (16 caucasians and 6 AA) with normal renal function undergoing AD, started within the last 9 months were randomized to receive (Arm A) CaCO3/vitamin D (500 mg/200U TID) or (Arm B) CaCO3/vitamin D and zoledronic acid (4 mg IV every 3 months for a year). Bone turnover markers including urine N-telopeptide, serum osteocalcin, serum bone specific alkaline phosphatase(BsAP) were serially measured every 3 months and bone mineral density (BMD) measured by DXA at hip, femur, spine and ward’s triangle at 0, 6 and 15 month intervals. Primary endpoint was to obtain BMD changes and bone turnover rates for each treatment arm. Nonparametric methods for analyzing longitudinal data were used to compare DXA-derived BMD measures and bone turnover rate markers in patients receiving zoledronic acid to the control group. Results: Data is presented for 16/22 patients who have completed 15- month follow up. Time trend analysis of bone formation (BsAP, osteocalcin) and resorption (N-telopeptide) markers and DXA measurements of BMD (spine and hip) are shown in the table. Conclusions: This study suggests that zoledronic acid preserves BMD at spine in racially diverse patients and, likewise provides preliminary estimates of BMD changes that occur over 15 months in patients receiving zoledronic acid and placebo. Larger AA cohorts are needed for prospective validation of the observed effect with zoledronic acid. [Table: see text] [Table: see text]

Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis

2014 ◽  
Author(s):  
Svetlana Yureneva ◽  
Oksana Yakushevskaya ◽  
Andrey Donnikov ◽  
Sergey Kuznetzov ◽  
Svetlana Mullambaeva ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

2007 ◽  
Vol 62 (8) ◽  
pp. 526-527 ◽  
Author(s):  
Dennis M. Black ◽  
Pierre D. Delmas ◽  
Richard Eastell ◽  
Ian R. Reid ◽  
Steven Boonen ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis

2010 ◽  
Vol 77 (1) ◽  
pp. 53-57 ◽  
Author(s):  
Patrice Fardellone ◽  
Bernard Cortet ◽  
Erick Legrand ◽  
Xavier Bresse ◽  
Ségolène Bisot-Locard ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Effectiveness Model

scholarly journals Efficacy of Oral Alendronate Versus Zoledronic Acid on Postmenopausal Osteoporosis

2019 ◽  
Vol 17 (2) ◽  
Author(s):  
Sharif Najafi ◽  
Zahra Rezasoltani ◽  
Kamran Azma ◽  
Saman Nayeb Abbas ◽  
Mehrdad Aghaei ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

scholarly journals Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease

2017 ◽  
Vol 8 (6) ◽  
pp. 294-302 ◽  
Author(s):  
Giampiero I. Baroncelli ◽  
Elena Ferretti ◽  
Cecilia M. Pini ◽  
Benedetta Toschi ◽  
Rita Consolini ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Turnover ◽  
Acid Treatment ◽  
Clinical Symptoms ◽  
Severe Form ◽  
Bone Lesions ◽  
Engelmann Disease
Sign in / Sign up

Export Citation Format

Share Document